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Abstract
Background: We analyzed the claim "mammography saves lives" by calculating the life-saving
absolute benefit of screening mammography in reducing breast cancer mortality in women ages 40
to 65.
Methods: To calculate the absolute benefit, we first estimated the screen-free absolute death risk
from breast cancer by adjusting the Surveillance, Epidemiology and End Results Program 15-year
cumulative breast cancer mortality to account for the separate effects of screening mammography
and improved therapy. We calculated the absolute risk reduction (reduction in absolute death risk),
the number needed to screen assuming repeated screening, and the survival percentages without
and with screening. We varied the relative risk reduction from 10%–30% based on the randomized
trials of screening mammography. We developed additional variations of the absolute risk
reduction for a screening intervention, including the average benefit of a single screen, as well as
the life-saving proportion among patients with earlier cancer detection.
Results: Because the screen-free absolute death risk is approximately 1% overall but rises with
age, the relative risk reduction from repeated screening mammography is about 100 times the
absolute risk reduction between the starting ages of 50 and 60. Assuming a base case 20% relative
risk reduction, repeated screening starting at age 50 saves about 1.8 (overall range, 0.9–2.7) lives
over 15 years for every 1000 women screened. The number needed to screen repeatedly is 1000/
1.8, or 570. The survival percentage is 99.12% without and 99.29% with screening. The average
benefit of a single screening mammogram is 0.034%, or 2970 women must be screened once to
save one life. Mammography saves 4.3% of screen-detectable cancer patients' lives starting at age
50. This means 23 cancers must be found starting at age 50, or 27 cancers at age 40 and 21 cancers
at age 65, to save one life.
Conclusion: The life-saving absolute benefit of screening mammography increases with age as the
absolute death risk increases. The number of events needed to save one life varies depending on
the prospective screening subset or reference class. Less than 5% of women with screen-detectable
cancers have their lives saved.
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Background
Under ideal conditions, a woman participates in screen-
ing mammography after deciding that the potential bene-
fit (increasing the length and quality of her life),
considering the limitations, outweighs the expected
harms and opportunity cost (time and money) [1]. Unre-
alistic expectations may influence a woman's decision.
Regarding the potential benefit of screening mammogra-
phy, two studies showed that over 90% of women think
"early detection saves lives" [2], and a woman with screen-
detected cancer "may have benefited" from mammogra-
phy [3]. A woman may turn to her doctor for advice, but
there is not universal agreement among physicians about
the wisdom of screening mammography, especially in
younger women ages 40 to 50 more susceptible to radia-
tion-induced cancer [4]. The 2002 U.S. Preventive Services
Task Force concluded that clinicians should stress that the
benefit/harm ratio of screening improves with age [5]. The
American College of Physicians recently advocated further
research into the net benefits and harms of screening
mammography in women ages 40 to 50 [6].
Furthermore, the components of informed medical deci-
sion-making regarding screening are not universally
accepted [7-9]. For example, the relative mortality risk
reduction (which makes screening sound more attractive)
[10] was emphasized in one recent review of the screening
mammography trials [11]. Many authors insist that the
absolute rather than relative risk reduction is the most
accurate way to describe a screening intervention [12,13].
Women are interested in knowing the absolute benefit
before their first or baseline mammography exam. In one
survey, 73% of women wanted to know the chance that
their lives "will be prolonged by getting a mammogram"
[14]. However, only 23% of these women were aware of
the absolute benefit before initiating screening, and only
2% had a complete discussion of screening with their phy-
sicians [15]. The National Cancer Institute comprehensive
web site provides only limited information, including the
optimistic declaration "Absolute benefit is approximately
1% overall but depends on inherent breast cancer risk,
which rises with age" [16].
Because popular claims such as "All women of the appro-
priate age should be screened" are often linked with the
mantra "good quality screening mammography saves
lives" [17], we decided to analyze how often this life-sav-
ing event occurs. Our goal was to help women and physi-
cians understand the stated purpose of mammography.
Ultimately, this knowledge is necessary to support con-
sumer-oriented informed medical decision-making. We
calculated the life-saving absolute benefit of screening
mammography as a continuous function of age in the tra-
ditional format of the absolute risk reduction from
repeated screening. To help women answer the question
"What do I gain from today's mammogram?" we also esti-
mated the average benefit of a single screening mammo-
gram. Finally, to answer the question "Did that screening
mammogram really save my life?" we derived the life-sav-
ing proportions from screening among women who
develop or have a mammography-detectable breast can-
cer.
Methods
Absolute benefit defined
Absolute risk is defined as the probability of a particular
event occurring over a specified period [18], such as the
chance that an average driver will be killed in an automo-
bile accident over 1 year. Three mathematically related
statistics can describe the absolute benefit from an inter-
vention or treatment designed to reduce the absolute risk
of an event. For example, the relative risk reduction (RRR)
might be the percentage reduction in non-fatal automo-
bile accident injuries over 1 year in a group of drivers with
an intervention of side airbags compared with a control
group without side airbags. For ease of understanding, we
will call the absolute risk reduction the reduction in abso-
lute risk. Therefore, the first statistic is reduction in abso-
lute risk = RRR * absolute injury risk, which can be
presented as a frequency or as a percentage. Assuming
hypothetically that the RRR of having side airbags is 30%,
and the 1-year automobile non-fatal absolute injury risk is
1.0% or 10/1000 for average drivers over 12,000 miles
[19], then the reduction in absolute risk would be 3/1000
((0.30 * 10) injuries/1000 drivers), or 0.3%.
The second statistic, the number needed to treat to prevent
one injury, is simply the reciprocal of the frequency form
of the reduction in absolute risk [20-22]. In our example,
the number of automobiles with side airbags needed to
prevent one injury would be 333 (1000/3). Finally, the
third statistic is the event-free percentage, which is the
complement of the absolute risk in the untreated and
treated groups in percentage form [23]. In our example,
the event-free percentage over 1 year in automobiles with-
out side airbags would be 99.0% (1.0 – 10/1000), and
with airbags 99.3% (1.0 – 7/1000). The gain in the event-
free percentage is simply the reduction in absolute risk in
percentage form.
When the event is a death, the intervention causes a life-
saving absolute benefit that reduces an absolute death
risk. The absolute risk reduction equals the relative mortal-
ity risk reduction multiplied by the absolute death risk.
Therefore, the first statistic becomes the reduction in abso-
lute death risk or RADR = RRR * absolute death risk. The
second statistic is the number needed to treat to save one
life, and the third statistic is the survival percentage. We
also developed two additional statistics for the life-saving
absolute benefit for a screening intervention. These varia-
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tions include the average benefit from one screening exam
(using airbags for a long trip), as well as the life-saving
proportions among women who develop or have earlier
detection of cancer (lives saved for those in traffic acci-
dents). Therefore, the life-saving absolute benefit in
regards to screening has five forms: the RADR, number
needed to screen, and the survival percentage; as well as
the average benefit and the life-saving proportions.
Absolute death risk
The first step in calculating the life-saving absolute benefit
is to estimate the absolute death risk from breast cancer.
Returning to the automobile example, assume both
restraint use (seat belts) and vehicle improvements (anti-
lock brakes) contributed to a reduction in the annual
automobile accident absolute death risk over the last 2
decades since the promotion of seat belt use. To calculate
the absolute benefit of seat belts, RADR = RRR * absolute
death risk. If we used only the 1985 higher death risk with-
out accounting for vehicle improvements, we would over-
estimate the seat belt benefit. Likewise, using the 2005
lower death risk would underestimate the seat belt bene-
fit. To get the true seat belt benefit, we need to estimate a
new baseline automobile absolute death risk without seat
belts but with vehicle improvements. We can derive the
baseline risk by subtracting the benefit of vehicle
improvements from the 1985 higher death risk.
For breast cancer, we need to subtract the benefit of
improved breast cancer treatment from the prescreening
absolute death risk to get a new screen-free absolute death
risk of breast cancer. Fortunately, these data are now avail-
able. Based on computer modeling, Berry et al estimated
that screening mammography has been responsible for
46% (range 28%–65%) of the 30 percent breast cancer
mortality reduction from 1975–2000, with the remaining
54% (range 35%–72%) due to therapy [24].
Fletcher and Harris previously used the cumulative prob-
ability of breast cancer death to present absolute death
risk [1,25]. We obtained estimates of the cumulative prob-
ability of dying from DCIS and invasive breast cancer over
15 years by using the Surveillance, Epidemiology and End
Results (SEER) Program mortality data for both 1978–
1980 (higher pre-screening era death risk) [26,27] and
2002–2004 (lower current death and development risk)
[26,28]. The 15-year period matches the median follow-
up from analyses of the breast cancer screening rand-
omized controlled trials (RCT) [11,29]. We included
women ages 40 to 65 in 5-year age increments.
Therefore, to estimate the current therapy but screen-free
absolute death risk, we first needed to calculate a risk dif-
ference = H - L, with H = higher 1980 prescreen death risk
and L = lower 2004 current death risk. We started with the
SEER 1978–1980 death risk per 1000 women including
both DCIS and invasive cancer, e.g. for age 40 H = 5.95
(95% confidence interval (CI) 5.71–6.19). We subtracted
the 2002–2004 death risk, L = 3.73 (95% CI 3.64–3.81),
to obtain the risk difference or mortality improvement, H
- L = 2.22. The 95% CI is 1.96–2.48 using Monte Carlo
resampling. We multiplied the risk difference by the frac-
tion attributable to therapy or 0.54. We then subtracted
this therapy benefit (0.54 * 2.22 = 1.20) from the 1978–
1980 death risk to obtain a new screen-free absolute death
risk, e.g. 5.95 – 1.20 = 4.75 at age 40. We calculated the
range (4.30–5.32) by using interval analysis.
Reduction in absolute death risk
With the new screen-free absolute death risk from breast
cancer, we can calculate the life-saving absolute benefit of
screening knowing the RRR since RADR = RRR * absolute
death risk. The risk ratio of death from the RCT of
repeated screening mammography is the ratio of cumula-
tive follow-up breast cancer deaths in the screened group
to the deaths in the control group, adjusted by the person-
years in each group. The complement of the risk ratio is
the RRR of repeated screening [30]. Analyses of the screen-
ing trials estimate that the RRR is 16%–20% overall, 15%
for women under 50 and 22% for women over 50 after 14
years of follow-up [11,29]. We considered RRR values
from 10% to 30%, with a base case of 20%. Arguments
can be made that this value should be lower (RCT issues)
or higher (screening compliance) [31,32]. By multiplying
this RRR by the screen-free absolute death risk, we esti-
mated the cumulative RADR from repeated screening for
women in the United States. We used the RADR to calcu-
late the number needed to screen repeatedly (NNSR) and
the survival percentages.
Average benefit
The RRR from the analyses of the screening trials is due to
women undergoing multiple or repeated screening mam-
mograms over a median period of about 6 years. To esti-
mate the number of mammogram examinations needed
to save one life, the NNSR needs to be multiplied by the
median average number of screening rounds of 4.25
(range 2–9) [29]. Tabar et al previously used this
approach after analysis of one randomized trial; however,
the authors did not obtain age-specific estimates [33]. The
benefit of the first or baseline mammogram (prevalence
screen) is at least twice the benefit of repeated or subse-
quent exams (incidence screen) in terms of cancer detec-
tion [11]. Therefore, if we count the baseline
mammogram twice, the median number of screening
rounds would be 5.25 (range 3–10). Now, we can assume
that every single mammogram contributes equally to the
benefit from repeated screening, so the benefit/mammo-
gram would be independent of time. Therefore, the
number of mammogram examinations needed to save
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one life would be equal to the number needed to screen
once (NNSO) at some time during 6 years. The reciprocal
of the NNSO is the average life-saving absolute benefit of
one subsequent mammogram. The average benefit of the
baseline mammogram would be twice that for a subse-
quent exam. We calculated the range for the RADR, NNSR
and the number of mammogram examinations by using
interval analysis.
Life-saving proportions
We also estimated the fraction or proportion of women
with life-saving mammography in the two following
groups: those who will develop cancer, and those who can
have their cancer detected by screening mammography.
The numerator of the life-saving proportion (LSP) is the
screen-free absolute death risk multiplied by the RRR. The
denominator is the SEER 2002–2004 cumulative 15-year
probability of developing cancer, multiplied by the
chance of having that cancer detected (mammography
sensitivity), or the cumulative cancer detection rate
(CCDR). Therefore, the LSP = RADR/CCDR. We assumed
a cumulative sensitivity of 80% for repeated mammogra-
phy over the period of screening [16]. The reciprocal of
the LSP is the number of cancers needed to develop or be
detected (NND) to save one life. The maximum LSP
would occur with the highest possible screening benefit
by assuming no therapy improvements, so we calculated
this effect for a sensitivity analysis.
Life-saving percentages
We can summarize our results by converting the life-sav-
ing absolute benefit of mammography in the various
screening subsets that we have analyzed into the life-sav-
ing percentage of events in each subset. These prospective
subsets or reference classes [34] include women screened
once, women screened repeatedly, women who develop
cancer, women who have cancer detectable, and women
who die of cancer. These percentages answer the question,
"Will screening mammography save my life?" We also
presented our results in augmented and frequency formats
to increase comprehension [35].
To simplify our results, we also generated scatter plots of
death risk and development risk versus age in Excel
(Microsoft, Redmond WA). We determined the best-fit-
ting trend line by simple linear regression as defined by
the highest coefficient of variation (R2).
Results
Absolute death risk
Figure 1 shows the age dependence of the development
risk and the screen-free absolute death risk from breast
cancer. The development risk = [-0.040AGE2 + 5.63AGE -
129.6]/1000, R2 = .99. The absolute death risk varies
between 0.475% at age 40 to 1.274% at age 65. The best-
fit equation = [-0.006AGE2 + 0.96AGE - 23.9]/1000, R2 =
.99. Between the starting ages of 40 and 55 (1.05%), the
absolute death risk over 15 years more than doubles.
Between the ages of 50 (0.883%) and 60 (1.177%), the
absolute death risk is about 1%.
Reduction in absolute death risk
Figure 1 shows the RADR of repeated screening mammog-
raphy at different levels of RRR. For perspective, the first
column in each age group shows the 15-year development
risk. For example, at 20% RRR and starting at age 50,
repeated screening averts 1.8 breast cancer deaths (range
1.6–1.9) over 15 years for every 1000 women screened.
The RADR varies from 2.4/1000 (2.3 to 2.5) at age 60, to
1.0/1000 (0.9 to 1.1) at age 40. The age/RRR extremes of
the RADR are 0.5/1000 at age 40/10% RRR, to 3.8/1000
at age 65/30% RRR, a ratio of 7.6. At the starting age of 53,
the RRR is 100 times the RADR or absolute risk reduction,
since the screen-free absolute death risk is 1% (RADR/
0.01 = RRR).
The reciprocal of the RADR is the NNSR, which is 1050
(940–1160) at age 40, 570 (520–620) at age 50, and 430
(400–450) at age 60. This means that if screening starts at
age 50, repeated screening of 570 mostly healthy women
saves one life among the many women who develop can-
cer over 15 years. The survival percentage shown in Table
1 is 100 times the complement of the absolute death risk
in the unscreened and screened groups. The survival per-
centage at age 50 without screening means that 99.12% of
women do not die from breast cancer over 15 years, which
improves to 99.29% at a 20% RRR with screening. The
gain in survival percentage is the RADR in percentage
form (0.177%). Figures 2 and 3 present the survival fre-
quencies starting at age 50 given selected RRR for all
women (from Table 1) and for women who develop
breast cancer, as well as cancer deaths and lives saved
(from Figure 1) using the reference class of 1000 average
women. We also included the reference class of 1000
high-risk women, defined as having twice the average can-
cer development and death risk.
Average benefit
Table 2 shows the number of mammogram examinations
needed to save one life. Assuming equivalent benefit from
all mammograms, this becomes equal to the NNSO. Start-
ing at age 50 and 20% RRR, screening 2970 women once
(range 1540–6160) will save one life over the next 15
years. This number is 5.25 times the NNSR of 570, or
5.25/RADR. The average benefit from one subsequent
mammogram would be 1/2970, or 0.034% chance of a
life saved. At age 40, assuming a 10% RRR, the NNSO
increases to 11050, and at age 60 at 30% RRR, decreases
to 1490.
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Life-saving proportions
Finally, Table 3 shows the proportion of women with
screen-detectable cancers that have their lives saved over
15 years through earlier treatment because of mammogra-
phy. The LSP ranges from 1.9% to 7.2% depending on age
and RRR. Assuming a 20% RRR starting at age 50, the life-
saving proportion is 4.3%, which falls to 3.7% at age 40
and increases to 4.6% at age 60. Therefore, the NND to
save one life starting at age 50 is the reciprocal of 4.3%, or
23.
Life-saving percentages
Using Figure 1 column 1, if we assume a group of 2000
40-year-old women, without screening, about 10 (4.8 * 2
= 9.6) will die of breast cancer over the next 15 years.
Assuming a low end 10% RRR for younger women instead
of the 20% base case, screening saves one of these 10, a
life-saving percentage of 10%. From the perspective of the
64 (31.9 * 2 = 63.8) of these 2000 women who will
develop cancer over 15 years, about 51 (0.8 * 64 = 51)
could have their cancer detected by screening. Table 3 col-
The life-saving absolute benefit or reduction in absolute death risk from repeated screening mammography according to ageFigur  1
The life-saving absolute benefit or reduction in absolute death risk from repeated screening mammography 
according to age. Data are from the Surveillance, Epidemiology, and End Results (SEER) Program including women ages 40 to 
65 in five-year age increments. The first column in each age group shows the 2002–2004 cumulative 15-year development risk 
for breast cancer for average women. The 1978–1980 cumulative 15-year absolute death risk from breast cancer (2nd column) 
is higher than the 2002–2004 death risk (3rd column) due to screening effects and better therapy. We multiplied plausible val-
ues for relative risk reduction (RRR) of 10% to 30% from repeated screening by the screen-free absolute death risk (4th col-
umn) to achieve estimates of the reduction in absolute death risk (RADR) from repeated screening (5th to 9th columns). The 
RADR is the same as the life-saving absolute benefit or absolute risk reduction. Starting at age 50 and 20% RRR, the RADR is 
1.8/1000. The numerator is the same as lives saved per 1000 women screened. Between the starting ages of 40 and 55, the life-
saving absolute benefit from mammography more than doubles, corresponding to the increased death risk. Between the start-
ing ages of 50 and 60, the RRR from repeated screening is about 100 times the absolute risk reduction since the screen-free 
absolute death risk is approximately 1%.
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umn 5 shows that repeated mammography will save one
of these 51 women, or a life-saving percentage of 1.9%
(0.019 * 51 = 0.97), but 0% of the 13 (64-51) women
whose cancer is not detectable. The RADR for all 2000
women undergoing repeated screening is 1/2000, or a life-
saving percentage of 0.05%. Using Table 2 column 2, if all
mammograms have equivalent benefit, then screening
about 11050 women once will save one life, a life-saving
percentage of 0.009%. By using the same methodology,
Figure 4 summarizes how often "mammography saves
lives" for the five prospective screening subsets. For the
age 50 base case, screening mammography saves 20% of
women who would die from cancer over 15 years. While
four of the prospective subsets have known death risks, we
would have to impute the death risk associated with the
single mammograms. The base case ratio of life-saving
absolute benefit high/low subsets is 130 (4.3/0.034). Fig-
ure 5 shows three subsets from Figure 4, each with a refer-
ence class having 1000 women.
Discussion
We have tried to explain the purpose of mammography by
answering the question: how often will screening mam-
mography "save" a woman's life? We have shown that
since the RADR = RRR * absolute death risk, the answer
for women undergoing repeated screening increases with
the age-related absolute death risk. For the age range 50 to
60, the screen-free absolute death risk for average women
is approximately 1%, so the RRR from repeated screening
is about 100 times the RADR or absolute risk reduction.
Frequency of survival for all women and women with cancer, deaths from breast cancer and lives saved from repeated screen-ing mammographyi ur  2
Frequency of survival for all women and women with cancer, deaths from breast cancer and lives saved from 
repeated screening mammography. Starting at age 50, 51 out of 1000 women will develop breast cancer over 15 years 
(Figure 1). In terms of natural frequencies, the 1000 healthy average-risk women are the reference class. Figure 2 Group A 
shows 991 out of 1000 women will survive (not die from) breast cancer by age 65 without screening. Group B shows that 42 
of the 51 breast cancer patients survive (positive framing) without screening. Therefore, nine women die (negative framing) 
without screening (Group C), and screening saves no lives (Group D). Assuming a 20% relative risk reduction (RRR) from 
repeated screening (row 3), mammography prevents two of nine deaths through earlier treatment, leaving seven cancer 
deaths. This means 44 of the 51 cancer patients and 993 of 1000 women will survive breast cancer.
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The life-saving absolute benefit also depends on the pro-
spective screening subset or reference class to which a
woman will belong. For women who will develop cancer,
the absolute death risk increases, so the life-saving abso-
lute benefit of mammography increases. Women who will
die of cancer have an absolute death risk of 100%, so the
life-saving absolute benefit is the maximum or the RRR.
For the base case age 50 and assuming a 20% RRR, women
with a screen-detectable cancer have a 4.3% chance of
Deaths from breast cancer and lives saved from repeated screening mammographyFigure 3
Deaths from breast cancer and lives saved from repeated screening mammography. Figure 3 is a magnification 
view of Groups C and D from Figure 2. Compared to Figure 1, the nine deaths without screening are the same as the screen-
free absolute death risk, while the lives saved are the same as the corresponding reduction in absolute death risk. Four out of 
1000 high-risk (double the average risk) women will have their lives saved assuming a 20% relative risk reduction (RRR).
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Table 1: Survival percentage: women not dying from breast cancer without and with repeated screening over 15 years.
Age No screening* 10% RRR† 20% RRR 30% RRR
with screening with screening with screening
40 99.52% 99.57% 99.62% 99.67%
45 99.32% 99.39% 99.45% 99.52%
50 99.12% 99.21% 99.29% 99.38%
55 98.95% 99.06% 99.16% 99.27%
60 98.82% 98.94% 99.06% 99.18%
65 98.73% 98.85% 98.98% 99.11%
* Survival percentage without screening is 100 times the complement of the screen-free absolute death risk from Figure 1.
† Survival percentage with screening is the same as the reduction in absolute death risk in percentage form from Figure 1 added to column 2 of this 
table.
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truth for the claim that "screening mammography saved
my life."
We can express the life-saving absolute benefit using per-
centage or frequency forms. The low extreme is the aver-
age benefit from a single mammogram of 1/11050 screens
(0.009% at age 40/10% RRR). The high extreme is the life-
saving proportion for women with a screen-detectable
cancer of 1/1370 (7.3% at age 65/30% RRR). For the base
case 20% RRR, the life-saving absolute benefit of a single
mammogram is 1/2970 screens, or 0.034%. For multiple
or repeated screening, the RADR is 1.8/1000, so the life-
saving percentage is 0.18%. Viewing these results from a
different perspective of the number of events needed to
save one life in each screening subset, the following values
are equivalent: five women dying of breast cancer, 23
women with screen-detectable cancers, 29 women with
cancers present, 570 women screened repeatedly, and
2970 women screened once. In other words, by subtract-
ing the one life saved in each prospective screening subset,
there is no life-saving absolute benefit for 22 women with
screen-detectable cancers, or for 2969 women screened
once.
Prior analyses
Our findings are close to other estimates of absolute ben-
efit from screening mammography, which will vary due to
the RRR and the cumulative period used. For instance, the
SEER 2002–2004 10-year cumulative risk of breast cancer
death from age 40 to 50 is 0.194%, versus 0.373% or
3.73/1000 (Figure 1) from age 40 to 55 [28], for a ratio of
0.52. Harris estimated that over a decade of regular screen-
ing the following lives would be saved over 15 to 20 years:
1.2–1.8/1000 at age 40, 1.9–3.9/1000 at age 50, and 5.9/
1000 at age 60 [25]. Fletcher et al estimated that assuming
10 years of annual screening, 2/1000 lives are saved over
20 years at age 40 (20% RRR) which increases to 4/1000
at age 50 (30% RRR) [1]. Barratt et al constructed a deci-
sion model of biannual screening for 10 years which pre-
dicts a RADR of 0.5/1000 at age 40 (23% RRR), and 1.9/
Table 2: Number of mammogram examinations needed to prevent one death.*
Age 10% RRR† 15% RRR 20% RRR Range 20%‡ 25% RRR 30% RRR
40 11050 7370 5530 2820–11630 4420 3680
45 7700 5130 3850 1980–8070 3080 2570
50 5950 3970 2970 1540–6160 2380 1980
55 5000 3330 2500 1320–5100 2000 1670
60 4460 2970 2230 1200–4450 1780 1490
65 4120 2750 2060 1130–4020 1650 1370
* Number of examinations is 5.25 times the number need to screen repeatedly (NNSR), which is the reciprocal of the reduction in absolute death 
risk (RADR) in Figure 1. The number needed to screen once (NNSO) is equivalent to the number of examinations if the benefit is the same for all 
mammograms. The average benefit of a subsequent screen is the inverse of the NNSO.
† The 5.25 median screens from the trials are responsible for the relative risk reduction (RRR) for repeated screening. We assumed the baseline 
exam has twice the benefit of a subsequent exam [11,29,33].
‡ The range is calculated by using interval analysis.
Table 3: Life-saving proportion: women with screen-detected cancers that have their lives saved by mammography.
Age Development risk/1000* CCDR/1000† Death risk/1000‡ 10%
RRR§
15%
RRR
20%
RRR
20%
NND||
25%
RRR
30%
RRR
20%
RRR
No Rx¶
% % % % % % %
40 31.9 25.5 4.8 1.9 2.8 3.7 27 4.7 5.6 4.7
45 41.9 33.5 6.8 2.0 3.0 4.1 25 5.1 6.1 5.1
50 51.0 40.8 8.8 2.2 3.2 4.3 23 5.4 6.5 5.3
55 59.2 47.3 10.5 2.2 3.3 4.4 23 5.5 6.7 5.2
60 64.4 51.5 11.8 2.3 3.4 4.6 22 5.7 6.9 5.1
65 66.3 53.0 12.7 2.4 3.6 4.8 21 6.0 7.2 5.0
* Cumulative 15-year development risk for breast cancer for average women, from Figure 1 [28].
† Cumulative cancer detection rate (CCDR) over 15 years assumes a cumulative sensitivity of 80% from repeated screening.
‡ Breast cancer screen-free absolute death risk is from Figure 1.
§ The proportion is the screen-free absolute death risk multiplied by the relative risk reduction (RRR), and then divided by the CCDR.
|| Number of cancers needed to be detected (NND) is the reciprocal of the life-saving proportion.
¶ Assumes maximum prescreening era (1978–1980) 15-year absolute death risk, with no adjustment for improved therapy.
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1000 at age 50 and 3.0/1000 at age 60 (37% RRR) [36].
Schwartz et al estimated a 10 year absolute risk reduction
of 0.8/1000 ages 40 to 49 (24% RRR), and 3/1000 ages 50
to 70 (33% RRR) [37]. Estimates of the NNSR from all the
trials for women under age 50 given a 15% RRR are 1792
(95% CI 764–10540) or absolute risk reduction of 0.56/
1000 (95% CI 0.09–1.31) which decreases to 838 (95%
CI 494–1676) assuming a 22% RRR for women 50 and
over [6,29].
Tabar et al found that the NNSR estimate from a single
trial without any analysis of the effect of a woman's age
was 465 (95% CI 324–819) over 20 years, given a 30%
RRR, while the number of mammogram examinations
was 1499 (95% CI 1046–2642) [33]. This estimate is
lower than our value of 1980 (range 1030–4110) at age
50. If we adjust the absolute death risk to 10 years from 15
and we use a 17% RRR starting at age 40 [28], we calculate
an absolute risk reduction of 0.4/1000 (0.95 * 0.52 * 0.85
= 0.42). This estimate matches the result from the recent
single randomized screening trial limited to younger
women under 50 and beginning at age 40 [38]. The over-
all RADR over 10 years recently calculated for all the RCT
of screening mammography is 0.05% or 0.5/1000 [31].
Will screening mammography save my life?Figure 4
Will screening mammography save my life?. The answer depends on the reference class. The life-saving absolute benefit 
of mammography increases as the absolute death risk in the woman's prospective screening subset increases. For women 
starting at age 50 and assuming a 20% relative risk reduction (RRR), the chance that "mammography saves lives" appears as the 
bottom row for each of the five screening subsets. For instance, mammography saves 4.3% of screen-detectable cancer 
patients' lives (subset B). These life-saving percentages correspond to the RRR (A: Breast cancer deaths), life-saving propor-
tions (B&C), reduction in absolute death risk (D: Repeated screening mammography – see Figure 1), and average benefit (E: 
Single mammogram). For a 20% RRR, the underlying absolute death risk (middle row) is five times the life-saving percentage. 
The number of events needed to save one life in each subset is the reciprocal of the life-saving percentage and increases from 
the smallest subset A (5) to the largest subset E (2970). Potential screening harm (top row, 100% minus bottom row) for 
women with cancer includes overdiagnosis, overtreatment, and delayed diagnosis. The potential harm for healthy women 
includes false-positive evaluations and biopsies, screening associated anxiety, and radiation-induced cancer.
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Mammography benefit
First, we have quantified how the life-saving absolute ben-
efit of mammography gradually increases with age, which
is important for younger women considering the age at
which to begin screening [5,6]. For example, the RADR at
age 65 is 2.7 times the RADR at age 40. Second, we have
estimated the life-saving absolute benefit from a single
mammogram. This statistic is useful because women
make the decision to screen about 30 million times in the
United States each year [39]. The average benefit rein-
forces the fact that the RRR from screening depends on
multiple or repeated exams, and it eliminates the assump-
tions regarding the frequency and length of screening.
Finally, we have challenged the popular perception that
earlier detection through mammography helps most
patients with screen-detected breast cancer [2,3].
Our analysis of "mammography saves lives" addresses a
knowledge gap and may facilitate better information
exchange before women initiate screening [15]. Many
women consistently overestimate the true benefit of
screening mammography, most importantly by confusing
primary and secondary prevention. For instance, two
recent surveys showed that over half of women think that
mammography acts like a vaccine by preventing or reduc-
ing the risk of contracting breast cancer [40,41]. This mis-
understanding is analogous to thinking that seat belts are
like antilock brakes and can prevent traffic accidents as
well as accident deaths. In a study almost a decade ago,
women under 50 had a greatly inflated perception of the
absolute risk (20 times) of dying from cancer over 10
years, and the absolute risk reduction (over 120 times)
derived from screening. These findings were consistent
with the perception that most breast cancer is rapidly fatal
and that women falsely equate diagnosis risk with death
risk [42]. This confusion is not surprising considering the
one in eight (12.3%) cumulative development risk for
breast cancer between the ages of 40 to 80 is rarely linked
with the one in 50 (2.0%) cumulative death risk for breast
cancer during the same time span [28]. SEER data in Fig-
ure 1 show the current 15-year cumulative diagnosis or
development risk is about seven times the cumulative
death risk, which implies a long average survival after
diagnosis [43].
Consequently, women should have improved insight and
reduced anxiety with a balanced presentation of the abso-
lute benefit of mammography in terms of the diagnosis
risk as well as the death risk [42]. Table 3 shows that more
than 95% of the time, screening mammography will not
save a screen-detectable cancer patient's life. This finding
is counter-intuitive since "Women view breast cancer as a
uniformly progressive disease rarely curable unless caught
early" [2]. In reality, breast cancer is a heterogeneous dis-
ease that may be systemic from the start or never metasta-
size [44]. Yet the belief in the exaggerated efficacy of
earlier detection is widespread: a recent survey of cancer
screening attitudes found that 74% of the general popula-
tion believes that finding cancer early saves lives most or
all of the time [45]. Assuming 100% cumulative sensitiv-
ity of mammography, the upper limit of the LSP would be
at most the RRR (10%–30%), and only if the death risk
were equal to the development risk.
Screening promotion
One reason for the public's confusion is that screening sta-
tistics can be difficult for even highly educated physicians
to understand, and this innumeracy presents a roadblock
to consumer insight about the true benefit of mammogra-
phy [10]. Rather than address innumeracy and promote
informed decision-making [46], most health organiza-
tions encourage high participation rates [2], rationalized
in the interest of "public" health [47]. The recent single
randomized screening mammography trial limited to
younger women under 50 and beginning at age 40 found
a statistically non-significant 17% RRR [38]. Despite this
finding, the American Cancer Society still has a goal to
increase screening mammography participation in
women over 40 from 67% to 90% by 2010 [48]. Analysts
also reveal a preference for screening uptake rather than
insight when they express concern about any decrease in
mammography utilization [49-51].
Figure 4 supports the analysis by Berry that screening
mammography is a lottery [52]. Screening advocates indi-
rectly acknowledge this analogy by focusing on the jack-
pot (mammography saves lives) rather than the average
gain. One estimate of the average gain to a woman after a
decade of screening is an extra week of life. This 1 week
gain ignores substantial "private" psychological costs
(including false-positive mammogram and biopsy-
induced anxiety), which would reduce the average gain to
between 2 and 3 days [53]. This adjusted gain is likely less
than the total time lost by a woman in order to get the
mammograms. Yet unlike a lottery ticket, there is no fine
print discussing the long odds of saving a life on the back
of screening reminder letters [54].
Besides the opportunity cost of time and money (buying
the ticket), authorities acknowledge that screening mam-
mography harms include a 30% increase in overdiagnosis
and overtreatment, delayed diagnosis, and radiation-
induced cancers [16,31,55]. One survey showed that phy-
sicians discuss these harms with women only 7% of the
time before the baseline mammogram [15]. One reason
may be that authors often ignore these harms in scientific
articles about screening mammography [56]. By this time,
editors, scientists and physicians should know and
acknowledge the potential problems and inherent biases
with screening [37,57-59].
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Instead of providing professional even-handed advice,
breast radiologists usually enthusiastically promote
expensive new screening technologies developed by the
medical imaging industry despite the drawbacks
[8,17,60,61]. For example, digital mammography may
have decreased sensitivity in older women (who are more
likely to get cancer), as well as increased false-positive
examinations and biopsies related to digital technology
linkage with computer-aided diagnosis [62]. Magnetic res-
onance and ultrasound imaging both substantially
increase recall rates, and neither technology has any
proven mortality benefit [63,64]. Consumers need to
keep in mind that fundamentally, cancer testing is a busi-
ness [18,52]. Breast radiologists, equipment manufactur-
ers [65], and advocacy groups [66] all have a conflict of
interest due to financial incentives. These incentives create
the temptation to exaggerate the benefits and dismiss the
harms of screening for breast cancer when advertising to
the public. As one proponent of informed decision-mak-
ing observes, excessive fear of breast cancer helps certain
interest groups but is not in the best interest of women
[10].
Consumer education
Voluntary informed participation requires that women
and their physicians understand that earlier detection and
treatment of breast cancer through screening mammogra-
phy (and possibly through other imaging technology) cer-
tainly saves some lives, but includes significant harms to
many women with and without cancer. Figure 1 shows
how the absolute death risk increases substantially with
age, and that many women die with breast cancer, not from
breast cancer. Education campaigns for breast cancer
awareness that want to promote insight rather than
uptake should stress the death risk from breast cancer
along with the development risk. For example, Figure 5
Frequency of lives saved from screening mammography for 1000 women in three prospective screening subsetsigur  5
Frequency of lives saved from screening mammography for 1000 women in three prospective screening sub-
sets. Figure 5 is a magnification view for subsets B, C, and D from Figure 4 but with 1000 women in each reference class. The 
frequency of breast cancer deaths without screening and the frequency of lives saved from mammography are equivalent to the 
percentages in Figure 4. The top row is the difference, or the breast cancer deaths despite screening in each subset. Compared 
to Figure 3, the nine deaths without screening and the seven cancer deaths and two lives saved with screening starting at age 
50 and 20% relative risk reduction are equivalent.
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shows that given 1000 breast cancer patients and a 173/
1000 death risk without screening, 827/1000 cancer
patients are "cured" or live a long time without mammog-
raphy.
We have shown that between the starting ages of 50 and
60, the RADR or absolute risk reduction is only about 1%
of the RRR. In order to address the problem of innumer-
acy, health organizations should advertise the absolute
death risk and the absolute benefits along with the corre-
sponding RRR [67,68]. Figures 4 and 5 show that if
women misapply the RRR by using a reference class
besides breast cancer deaths, they will overestimate the
absolute benefit of screening [34]. To avoid manipulation
and to foster insight, health organizations should frame
the risk or benefit by using both positive terms (absence
of disease or survival) and negative terms (presence of dis-
ease or death) [46,69]. For example, Figure 5 shows that
screening would save 35 but would not save 138 of the
173 women who die from breast cancer. From Table 1,
younger women at age 40 have a 99.5% chance of not
dying from breast cancer before age 55, which improves to
99.6% with regular screening (a gain in survival percent-
age of 0.1%, not 1.0%) [16].
Analysts can best communicate statistical information by
using natural frequencies (event counts using one refer-
ence class) or clarifying the reference class [34]. For
instance, assuming 2970 single screening mammograms
are required to save one life starting at age 50 (Table 2),
this means that about 370 (12.4/100) women will be
recalled for additional testing with associated psychologi-
cal distress, and about 62 (2.1/100) biopsies will be
required [70]. For repeated screening and using a 16%
RRR [29] (Table 3), screening mammography prevents
three to four deaths over 15 years in 100 screen-detected
cancer patients under age 65. Approximately 30 of the
remaining women will experience overdiagnosis and
overtreatment, including mastectomies and radiation
treatment that can cause heart disease [31,71].
A comparison with equivalent risks will help put the
death risk from breast cancer in perspective. For example,
the cumulative death risk from lung cancer is 0.93% or
9.3/1000 between the ages of 50 and 65 [28], similar to
the death risk from breast cancer of 0.88% or 8.8/1000.
The absolute risk of dying as a vehicle occupant in an
automobile accident projected over 15 years driving
12,000 miles a year is 0.205% or 2.05/1000 [19]; this
death risk is equal to our base case life-saving absolute
benefit of screening mammography of 1.8/1000 if a
woman drives 10,300 miles a year. The lifetime develop-
ment risk for coronary heart disease for women over age
40 of 25%–32% is at least twice the development risk for
breast cancer [72].
Limitations
From the RCT survival curves, analysts cannot tell if the
mortality reduction associated with screening mammog-
raphy is due to either a "cure" or "reduction in hazard".
We have assumed that a "life saved" means screening
helps cure one woman with breast cancer who would have
otherwise died from the disease without screening. The
end result from a cure is that a woman lives a normal life
span beyond the point of expected death from breast can-
cer. However, all women with cancer may theoretically
benefit from screening mammography through slowing
the disease and therefore slightly prolonging their lives.
These women would experience life extension but would
still die from breast cancer. The source of the survival ben-
efit from screening mammography may lie somewhere in
between individual life saving and multiple smaller life
extensions, so the distribution of women actually benefit-
ing in some way from screening (although the total effect
is the same) is not known [73].
In economic theory, the marginal cost of a defensive
measure taken to reduce the risk to health and life must be
less than the marginal benefit from the reduced probabil-
ity of disease and death, or the action should not be
undertaken [74]. Therefore, deriving the equivalence of
"saving a life" in terms of a present-value quality-adjusted
amount of life saved per women screened would simplify
the expected benefit from screening and help women
make better decisions [75]. The marginal cost per women
screened includes the expected opportunity cost (time,
travel, and resource costs) and the expected harms
(including anxiety and overtreatment). Multiple factors
will influence this economic analysis, including a
woman's attitude toward risk. Younger women have
longer normal lives than older women and more poten-
tial years to save through screening mammography. On
the other hand, older women have more potential cancer
to find through the increasing incidence of breast cancer
with age [62]. Furthermore, there may be a benefit of
screening other than mortality reduction through reduced
morbidity from less aggressive breast cancer treatment.
However, women must weigh this possible benefit against
the effect of screening-induced overdiagnosis and over-
treatment [55].
Our study is limited because the screening effect on the
absolute risk of death from any cause may be more mean-
ingful than the screening effect on breast cancer mortality
from the RCT [18,76]. Our base case assumption of a 20%
RRR due to screening may be optimistic and is probably
closer to 15% [29,31]. Finally, further analysis of the rela-
tive contribution of the baseline versus the subsequent
mammogram in reducing breast cancer mortality may
produce a better estimate of the average benefit of a single
mammogram.
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Conclusion
We have shown how the life-saving absolute benefit of
screening mammography gradually increases with age as
the screen-free absolute death risk increases, since RADR =
RRR * absolute death risk. For 50- to 60-year-old women,
the screen-free absolute death risk over 15 years is approx-
imately 1%, so the RRR for repeated screening mammog-
raphy is about 100 times the RADR or absolute risk
reduction. The chance that "mammography saves lives"
depends on the absolute death risk in the prospective
screening subset or reference class to which a woman
belongs. For a woman in the screening subset of mam-
mography-detectable cancers, there is a less than 5%
chance that a mammogram will save her life. By compar-
ing screening mammography's life-saving absolute bene-
fit with its expected harms and her opportunity cost, a
well-informed woman along with her physician can make
a reasonable decision to screen or not to screen for breast
cancer.
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